A Phase 2 interventional study of Fezolinetant and Placebo in Menopause and Hot Flashes, sponsored by Astellas Pharma Global Development, Inc.. Completed at 51 sites in United States. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-11-26.
Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing fezolinetant in Hot Flashes — 4 open to participants now, 5 under way, 4 of them phase 3. fezolinetant · Hot Flashes.
Among the 16 studies testing fezolinetant in Hot Flashes, this one is the 6th largest by enrollment, is the only one that started in 2017, is one of 5 in phase 2, and was the 1st registered.
339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.
Browse Hot Flashes studies →4 of the 16 studies testing fezolinetant in Hot Flashes are open now, in 2 countries. Recruiting first, the newest first:
Astellas Pharma Inc · Sites in India
Ages 18+ · Women only
University of Colorado, Denver · Sites in United States
Ages 45–55 · Women only · Healthy volunteers
University of Vermont · Sites in United States
Ages 18+ · Men only
Rebecca Thurston · Sites in United States
Ages 40–65 · Women only
By country, each count listing its studies:
fezolinetant: first FDA approval 2023 (VEOZAH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 40 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 11
First in 2015; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 356 is above the median of 90 across 306 interventional studies indexed under Hot Flashes.
Median enrollment 249 across the 16 interventional studies. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 16 have an industry lead sponsor. The 7 most frequent:
This study is registered under Astellas Pharma Global Development, Inc., one of the names counted as Astellas Pharma Inc. Under that name alone:
Astellas Pharma Global Development, Inc. is the lead sponsor of 207 studies on the registry; 23 are open to participants now.
Of its 82 completed or terminated interventional studies of FDA-regulated products, 38 (46%) have results posted.
16 studies in Hot Flashes by Astellas Pharma Inc: 2 open now, 3 under way, 2 of them phase 3. Of 13 finished, 5 (38%) have results posted.
Among the 16 studies in Hot Flashes by Astellas Pharma Inc, this one is the 6th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2017, is one of 4 in phase 2, and was the 1st registered.
Astellas Pharma Inc’s Hot Flashes studies by the year they started, since 2015.
1 of the studies testing fezolinetant in Hot Flashes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06972875University of VermontFezolinetant for Treating Hot Flashes in Men With Prostate Cancer | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies testing fezolinetant in Hot Flashes, from their registry updates:
Among Astellas Pharma Inc’s 16 in Hot Flashes:
This tab as a report to print or save as PDF → With an account.
This study determined the effects of different doses and dosing regimens of ESN364 on the frequency and severity of hot flashes. The treatment was administered for 12 weeks to postmenopausal women, aged 40 to 65, suffering at least 50 moderate to severe hot flashes per week.
This was a 12-week randomized, double-blind, placebo-controlled, dose-ranging, parallel-group, multi-center study to assess the efficacy of ESN364 in postmenopausal women suffering from vasomotor symptoms (hot flashes).
This study consisted of a screening period (Days -35 to -1, including the screening visit [Visit 1] and a minimum 7-day collection of baseline vasomotor symptom frequency and severity assessments), a 12 week treatment period (Day 1 [Visit 2] to Week 12 [Visit 5]), and a follow up visit (Week 15 [Visit 6]) 3 weeks after the last dose of study drug.
The study was performed on an ambulatory basis. The screening visit (Visit 1) occurred up to 35 days prior to randomization. Eligibility was assessed via physical examination, clinical laboratory testing, vital signs, ECG, Pap smear, mammography, and endometrial biopsy. Subjects received an electronic diary to record daily vasomotor symptoms during the duration of the screening period. Subjects who had ≥7 consecutive days of vasomotor symptom recordings participated in the study. Subjects are encouraged to continue recording for the duration of the whole screening period. The electronic diary was reviewed by study site staff on Day 1 (Visit 2) to confirm study eligibility. Subjects were rescreened 1 time upon approval of the medical monitor.
During the treatment period, subjects returned to the study site every 4 weeks for assessments.
The follow-up visit occurred approximately 3 weeks following the last dose of study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received fezolinetant matching placebo capsules orally, BID for a period of 12 weeks.
Drug: Fezolinetant
Participants received fezolinetant 15 mg capsules orally, BID for a period of 12 weeks.
Drug: Placebo
Participants received fezolinetant 30 mg capsules orally, BID for a period of 12 weeks.
Drug: Fezolinetant
Participants received fezolinetant 60 mg capsules orally, BID for a period of 12 weeks.
Drug: Fezolinetant
Participants received fezolinetant 90 mg capsules orally, BID for a period of 12 weeks.
Drug: Fezolinetant
Participants received fezolinetant 30 mg capsules orally, QD and matching placebo QD for a period of 12 weeks.
Drug: Fezolinetant
Participants received fezolinetant 60 mg capsules orally, QD and matching placebo QD for a period of 12 weeks.
Drug: Fezolinetant
Participants received fezolinetant 120 mg capsules orally, QD and matching placebo QD for a period of 12 weeks.
Drug: Fezolinetant
Oral Capsule
Also known as: ESN364
Oral Capsule
Co-Primary Efficacy Endpoint: Change From Baseline (CFB) in The Mean Frequency of Moderate to Severe Vasomotor Symptoms (VMS) at Week 4
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
Time frame: Baseline and week 4
Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 12
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
Time frame: Baseline and week 12
Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 4
Severity of moderate to severe VMS per day was calculated as follows: \[(number of moderate VMS × 2) + (number of severe VMS × 3)\]/number of daily moderate/severe VMS. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for participants that had no moderate or severe VMS. Higher score indicates greater severity.
Time frame: Baseline and week 4
Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 12
Severity of moderate to severe VMS per day was calculated as follows: \[(number of moderate VMS × 2) + (number of severe VMS × 3)\]/number of daily moderate/severe VMS. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for participants that had no moderate or severe VMS. Higher scores indicates greater severity.
Time frame: Baseline and week 12
Change From Baseline in The Mean Frequency of Mild, Moderate, and Severe VMS to Each Study Week
The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, subject does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
Time frame: Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Change From Baseline in The Mean Frequency of Moderate and Severe VMS to Each Study Week
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
Time frame: Baseline and weeks 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 13, 14 and 15
Change From Baseline in The Mean Severity of Mild, Moderate, and Severe VMS to Each Study Week
Severity of mild, moderate \& severe VMS per day was calculated as follows \[(number of mild VMS × 1) + (number of moderate VMS × 2) + (number of severe VMS × 3)\]/number of daily mild/moderate/severe VMS Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant did not wake up but later noticed damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot \& was sweating \& needed to take action Severity was zero for participants that had no moderate or severe VMS. Higher score indicates greater severity.
Time frame: Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Change From Baseline in The Mean Severity of Moderate and Severe VMS to Each Study Week
Severity of moderate to severe VMS per day was calculated as follows: \[(number of moderate VMS × 2) + (number of severe VMS × 3)\]/number of daily moderate/severe VMS. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for patients that had no moderate or severe VMS. Higher score indicates greater severity.
Time frame: Baseline and weeks 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 13, 14 and 15
Change From Baseline in The Hot Flash Score of Mild, Moderate, and Severe VMS to Each Study Week
The hot flash score per 24h (or 12 h day time or 12 h night time) of VMS (mild, moderate, and severe) is calculated as follows: (number of mild VMS x 1) + (number of moderate VMS x 2) + (number of severe VMS x 3). Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant did not wake up but later noticed damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Higher score indicates greater severity.
Time frame: Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Change From Baseline in The Hot Flash Score of Moderate and Severe VMS to Each Study Week
The hot flash score per 24h of moderate and severe VMS is calculated as follows: (number of moderate VMS x 2) + (number of severe VMS x 3). Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). VMS. Baseline is the average frequency of 24h vasomotor symptom from 7 non-missing days prior to Day 1. Higher score indicates greater severity.
Time frame: Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Mean Percent Reduction of Mild, Moderate, And Severe Vasomotor Symptoms From Baseline to Each Study Week
The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, subject does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
Time frame: Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Mean Percent Reduction of Moderate And Severe Vasomotor Symptoms From Baseline to Each Study Week
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
Time frame: Baseline and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Number of Participants With Mean Percent Reduction of 50% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week
The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, and 15
Number of Participants With Mean Percent Reduction of 70% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week
The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Number of Participants With Mean Percent Reduction of 90% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week
The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week
The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Number of Participants With Mean Percent Reduction of 50% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Number of Participants With Mean Percent Reduction of 70% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Number of Participants With Mean Percent Reduction of 90% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Number of Participants With Absolute Reduction of 2 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week
The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Number of Participants With Absolute Reduction of 3 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week
The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Number of Participants With Absolute Reduction of 4 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week
The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Number of Participants With Absolute Reduction of 5 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week
The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Number of Participants With Absolute Reduction of 2 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Number of Participants With Absolute Reduction of 3 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Number of Participants With Absolute Reduction of 4 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Number of Participants With Absolute Reduction of 5 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
Time frame: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Change From Baseline in Hot Flash-Related Daily Interference Scale (HFRDIS) at Weeks 4, 8, 12, and 15
The HFRDIS is a 10-item scale that measures a woman's perceptions of the degree to which VMS interfere with 9 daily life activities (work, social activities, leisure, sleep, mood, concentration, relations with others, sexuality, and enjoying life); the tenth item measures interference with overall quality of life. This scale was modeled after items on the Brief Pain Inventory and Brief Fatigue Inventory, which assess the extent to which pain or fatigue interfere with daily life. Participants were asked to rate the extent to which VMS had interfered with each item during the previous 2-week time interval using a 0 (do not interfere) to 10 (completely interfere) scale. Overall mean score is the average of individual item scores (sum of items/10).
Time frame: Baseline and weeks 4, 8, 12, and 15
Leeds Sleep Evaluation Questionnaire (LSEQ) Domain Scores at Weeks 4, 8, 12 and 15
The LSEQ is a 10-item self-rated questionnaire that assesses a participants aspects of sleep and early morning behavior. The questions are grouped into 4 chronological areas: ease of getting to sleep, perceived quality of sleep, ease of awaking from sleep, and integrity of early morning behavior following wakefulness. The LSEQ is a visual analog scale that requires respondents to place marks on a group of 10 cm lines. Lines extend between extremes like "more difficult than usual" and "easier than usual." Responses are measured using a 100 mm scale and are averaged to a score for each domain. Higher scores indicates better sleep and better early morning behavior.
Time frame: Weeks 4, 8, 12, and 15
Change From Baseline in Greene Climacteric Scale (GCS) at Weeks 4, 8, 12, and 15
The GCS is a 21-item scale that provides a brief but comprehensive and valid measure of climacteric symptomatology. Each item is rated by the participant according to its severity using a 4-point rating scale from 0 (none) to 3 (severe). The first 20 items of the scale combine into 3 main independent symptom measures by summing up the individual item scores: psychological symptoms (items 1 to 11; score 0 to 33), physical symptoms (items 12 to 18; score 0 to 21), and VMS (items 19 to 20; score 0 to 6). Item 21 is a probe for sexual dysfunction. The total score can range from 0 to 63. Higher scores indicate worse symptoms.
Time frame: Baseline and weeks 4, 8, 12, and 15
Change From Baseline in Menopause-Specific Quality of Life (MENQoL) at Weeks 4, 8, 12, and 15
The MENQoL is self-administered and consists of a total of 29 items in a Likert-scale format. Each item assesses the impact of 1 of 4 domains of menopausal symptoms, as experienced over the last month: vasomotor (items 1 to 3), psychosocial (items 4 to 10), physical (items 11 to 26), and sexual (items 27 to 29). Items pertaining to a specific symptom are rated as present or not present, and if present, how bothersome on a 0 (not bothersome) to 6 (extremely bothersome) scale. Means are computed for each subscale by dividing the sum of the domain's items by the number of items within that domain. Non-endorsement of an item is scored a "1" and endorsement a "2," plus the number of the particular rating, so that the possible score on any item ranges from 1 to 8. Higher scores indicate that menopause symptoms are more bothersome.
Time frame: Baseline and weeks 4, 8, 12, and 15
Change Over Time From Baseline in Plasma Concentrations of Luteinizing Hormone (LH) at Week 12
Change was calculated as the post-baseline measurement minus the baseline measurement. Baseline was the last measurement taken prior to initial study drug administration.
Time frame: Baseline and week 12
Change Over Time From Baseline in Plasma Concentrations of Follicle-Stimulating Hormone (FSH) at Week 12
Change was calculated as the post-baseline measurement minus the baseline measurement. Baseline was the last measurement taken prior to initial study drug administration.
Time frame: Baseline and week 12
Change Over Time From Baseline in Plasma Concentrations of Estradiol (E2) at Week 12
Change was calculated as the post-baseline measurement minus the baseline measurement. Baseline was the last measurement taken prior to initial study drug administration. The analysis value for Estradiol was imputed as 73.4/2 = 36.7 when result was \< 73.4.
Time frame: Baseline and week 12
Change Over Time From Baseline in Plasma Concentrations of Sex Hormone-Binding Globulin (SHBG) at Week 12
Change was calculated as the post-baseline measurement minus the baseline measurement. Baseline was the last measurement taken prior to initial study drug administration.
Time frame: Baseline and week 12
Postmenopausal women participants 40 to 65 years of age who had at least 50 moderate to severe vasomotor symptoms (VMS) per week and who met the inclusion criteria and none of the exclusion criteria were enrolled in this study.
| Milestone | Placebo BID | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Started | 44 | 45 | 44 | 45 | 44 | 45 | 45 | 44 |
| Treated | 43 | 45 | 43 | 45 | 44 | 43 | 45 | 44 |
| Completed | 37 | 40 | 38 | 33 | 32 | 34 | 36 | 37 |
| Not completed | 7 | 5 | 6 | 12 | 12 | 11 | 9 | 7 |
| Withdrew: Adverse event | 1 | 0 | 4 | 5 | 3 | 2 | 3 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 2 | 3 | 1 | 1 | 1 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 | 0 | 2 | 1 | 0 |
| Withdrew: Protocol deviation | 1 | 1 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 4 | 0 | 4 | 3 | 4 | 4 | 2 |
| Withdrew: Miscellaneous | 1 | 0 | 1 | 1 | 1 | 2 | 0 | 1 |
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
| VMS per day | Placebo BID | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Co-Primary Efficacy Endpoint: Change From Baseline (CFB) in The Mean Frequency of Moderate to Severe Vasomotor Symptoms (VMS) at Week 4 | -4.2 ± 0.65 | -6.1 ± 0.65 | -7.2 ± 0.64 | -7.0 ± 0.62 | -7.7 ± 0.65 | -6.5 ± 0.65 | -7.2 ± 0.61 | -6.6 ± 0.63 |
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
| VMS per day | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 12 | -5.3 ± 0.58 | -7.2 ± 0.54 | -7.5 ± 0.56 | -7.6 ± 0.55 | -8.0 ± 0.58 | -7.4 ± 0.58 | -7.9 ± 0.54 | -7.4 ± 0.57 |
Severity of moderate to severe VMS per day was calculated as follows: \[(number of moderate VMS × 2) + (number of severe VMS × 3)\]/number of daily moderate/severe VMS. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for participants that had no moderate or severe VMS. Higher score indicates greater severity.
| Score on a scale | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 4 | -0.3 ± 0.15 | -0.8 ± 0.14 | -0.9 ± 0.15 | -1.2 ± 0.14 | -1.3 ± 0.15 | -0.7 ± 0.15 | -0.9 ± 0.14 | -1.0 ± 0.15 |
Severity of moderate to severe VMS per day was calculated as follows: \[(number of moderate VMS × 2) + (number of severe VMS × 3)\]/number of daily moderate/severe VMS. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for participants that had no moderate or severe VMS. Higher scores indicates greater severity.
| Score on a scale | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 12 | -0.8 ± 0.16 | -1.0 ± 0.15 | -1.1 ± 0.16 | -1.3 ± 0.16 | -1.4 ± 0.17 | -0.9 ± 0.16 | -1.3 ± 0.15 | -1.1 ± 0.16 |
The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, subject does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
| VMS per day | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Week 1 | -2.0 ± 0.60 | -3.4 ± 0.56 | -4.7 ± 0.59 | -5.5 ± 0.58 | -6.1 ± 0.61 | -3.0 ± 0.61 | -4.4 ± 0.56 | -4.8 ± 0.59 |
| Week 2 | -3.6 ± 0.62 | -4.9 ± 0.58 | -6.3 ± 0.61 | -6.8 ± 0.60 | -7.3 ± 0.63 | -5.1 ± 0.63 | -5.4 ± 0.59 | -6.0 ± 0.61 |
| Week 3 | -3.8 ± 0.63 | -5.6 ± 0.60 | -6.8 ± 0.62 | -7.3 ± 0.61 | 7.7 ± 0.64 | -5.8 ± 0.64 | -6.1 ± 0.60 | -6.6 ± 0.62 |
| Week 4 | -4.0 ± 0.63 | -5.7 ± 0.60 | -7.0 ± 0.62 | -7.2 ± 0.61 | -8.1 ± 0.64 | -6.0 ± 0.64 | -6.8 ± 0.60 | -7.1 ± 0.62 |
| Week 5 | -4.6 ± 0.60 | -5.8 ± 0.57 | -7.2 ± 0.59 | -7.6 ± 0.58 | -8.5 ± 0.61 | -6.6 ± 0.61 | -6.8 ± 0.56 | -7.1 ± 0.59 |
| Week 6 | -4.9 ± 0.60 | -6.2 ± 0.57 | -7.2 ± 0.59 | -8.0 ± 0.58 | -8.6 ± 0.62 | -6.6 ± 0.61 | -7.1 ± 0.57 | -7.6 ± 0.59 |
| Week 7 | -4.9 ± 0.61 | -6.2 ± 0.58 | -7.4 ± 0.60 | -7.8 ± 0.59 | -8.7 ± 0.63 | -6.8 ± 0.62 | -7.2 ± 0.58 | -7.7 ± 0.60 |
| Week 8 | -5.5 ± 0.61 | -6.2 ± 0.58 | -7.5 ± 0.60 | -8.1 ± 0.60 | -8.5 ± 0.63 | -6.8 ± 0.63 | -7.4 ± 0.58 | -7.8 ± 0.61 |
| Week 9 | -5.8 ± 0.59 | -6.8 ± 0.55 | -7.5 ± 0.57 | -8.3 ± 0.57 | -8.7 ± 0.60 | -6.8 ± 0.60 | -7.7 ± 0.56 | -7.9 ± 0.58 |
| Week 10 | -5.6 ± 0.60 | -7.0 ± 0.57 | -7.1 ± 0.59 | -8.3 ± 0.59 | -8.7 ± 0.62 | -7.2 ± 0.62 | -7.8 ± 0.58 | -8.0 ± 0.60 |
| Week 11 | -5.7 ± 0.59 | -7.0 ± 0.56 | -7.5 ± 0.58 | -8.7 ± 0.58 | -8.6 ± 0.61 | -7.3 ± 0.60 | -8.0 ± 0.56 | -8.0 ± 0.59 |
| Week 12 | -5.7 ± 0.58 | -7.1 ± 0.54 | -7.6 ± 0.57 | -8.5 ± 0.57 | -8.8 ± 0.59 | -7.4 ± 0.59 | -8.0 ± 0.55 | -8.1 ± 0.57 |
| Week 13 | -4.7 ± 0.65 | -5.9 ± 0.58 | -5.1 ± 0.60 | -4.9 ± 0.63 | -5.7 ± 0.64 | -6.1 ± 0.65 | -5.9 ± 0.62 | -5.5 ± 0.61 |
| Week 14 | -4.4 ± 0.65 | -5.2 ± 0.58 | -4.5 ± 0.60 | -4.5 ± 0.63 | -5.0 ± 0.64 | -5.6 ± 0.65 | -5.7 ± 0.63 | -5.1 ± 0.61 |
| Week 15 | -4.9 ± 0.62 | -4.5 ± 0.56 | -4.7 ± 0.58 | -4.2 ± 0.62 | -4.5 ± 0.62 | -4.6 ± 0.64 | -5.6 ± 0.61 | -4.7 ± 0.59 |
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
| VMS per day | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Week 1 | -2.1 ± 0.59 | -3.8 ± 0.56 | -5.3 ± 0.58 | -5.7 ± 0.57 | -6.4 ± 0.60 | -3.3 ± 0.60 | -4.7 ± 0.56 | -4.7 ± 0.58 |
| Week 2 | -3.7 ± 0.60 | -5.3 ± 0.57 | -6.8 ± 0.59 | -6.8 ± 0.58 | -7.3 ± 0.61 | -5.4 ± 0.61 | -6.0 ± 0.57 | -5.7 ± 0.59 |
| Week 3 | -3.7 ± 0.61 | -5.8 ± 0.58 | -7.3 ± 0.60 | -7.0 ± 0.59 | -7.7 ± 0.62 | -6.3 ± 0.62 | -6.9 ± 0.58 | -6.3 ± 0.60 |
| Week 5 | -4.5 ± 0.58 | -6.3 ± 0.55 | -7.6 ± 0.57 | -7.3 ± 0.56 | -8.3 ± 0.59 | -6.9 ± 0.59 | -7.3 ± 0.55 | -6.7 ± 0.57 |
| Week 6 | -4.8 ± 0.58 | -6.6 ± 0.55 | -7.5 ± 0.57 | -7.6 ± 0.57 | -8.3 ± 0.60 | -7.0 ± 0.60 | -7.5 ± 0.55 | -7.1 ± 0.58 |
| Week 7 | -4.9 ± 0.59 | -6.5 ± 0.56 | -7.7 ± 0.58 | -7.5 ± 0.58 | -8.4 ± 0.61 | -7.1 ± 0.60 | -7.4 ± 0.56 | -7.2 ± 0.59 |
| Week 8 | -5.5 ± 0.59 | -6.6 ± 0.56 | -7.6 ± 0.58 | -7.7 ± 0.58 | -8.3 ± 0.61 | -7.1 ± 0.61 | -7.7 ± 0.56 | -7.3 ± 0.59 |
| Week 9 | -5.7 ± 0.57 | -7.1 ± 0.54 | -7.7 ± 0.56 | -8.0 ± 0.56 | -8.4 ± 0.59 | -7.1 ± 0.59 | -7.9 ± 0.54 | -7.3 ± 0.57 |
| Week 10 | -5.4 ± 0.59 | -7.2 ± 0.56 | -7.5 ± 0.58 | -7.9 ± 0.58 | -8.3 ± 0.61 | -7.4 ± 0.60 | -7.8 ± 0.56 | -7.6 ± 0.59 |
| Week 11 | -5.5 ± 0.57 | -7.3 ± 0.54 | -7.8 ± 0.56 | -8.3 ± 0.56 | -8.3 ± 0.59 | -7.6 ± 0.58 | -8.0 ± 0.54 | -7.6 ± 0.57 |
| Week 13 | -4.4 ± 0.65 | -6.4 ± 0.58 | -5.4 ± 0.60 | -5.3 ± 0.63 | -5.7 ± 0.64 | -6.8 ± 0.65 | -6.0 ± 0.62 | -5.2 ± 0.61 |
| Week 14 | -4.1 ± 0.66 | -5.7 ± 0.60 | -4.5 ± 0.61 | -4.8 ± 0.65 | -5.0 ± 0.66 | -6.2 ± 0.67 | -5.8 ± 0.65 | -4.8 ± 0.63 |
| Week 15 | -4.6 ± 0.65 | -5.1 ± 0.59 | -4.5 ± 0.60 | -4.5 ± 0.65 | -4.4 ± 0.65 | -5.6 ± 0.67 | -5.5 ± 0.65 | -4.4 ± 0.61 |
Severity of mild, moderate \& severe VMS per day was calculated as follows \[(number of mild VMS × 1) + (number of moderate VMS × 2) + (number of severe VMS × 3)\]/number of daily mild/moderate/severe VMS Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant did not wake up but later noticed damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot \& was sweating \& needed to take action Severity was zero for participants that had no moderate or severe VMS. Higher score indicates greater severity.
| Score on a scale | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Week 1 | -0.2 ± 0.09 | -0.5 ± 0.08 | -0.5 ± 0.09 | -0.6 ± 0.09 | -0.8 ± 0.09 | -0.2 ± 0.09 | -0.5 ± 0.08 | -0.5 ± 0.09 |
| Week 2 | -0.2 ± 0.11 | -0.6 ± 0.11 | -0.7 ± 0.11 | -1.0 ± 0.11 | -1.1 ± 0.11 | -0.4 ± 0.11 | -0.7 ± 0.11 | -0.8 ± 0.11 |
| Week 3 | -0.3 ± 0.13 | -0.8 ± 0.12 | -0.9 ± 0.13 | -1.1 ± 0.12 | -1.2 ± 0.13 | -0.6 ± 0.13 | -0.9 ± 0.12 | -1.0 ± 0.13 |
| Week 4 | -0.3 ± 0.13 | -0.8 ± 0.12 | -1.0 ± 0.13 | -1.1 ± 0.13 | -1.4 ± 0.13 | -0.8 ± 0.13 | -0.9 ± 0.12 | -1.1 ± 0.13 |
| Week 5 | -0.5 ± 0.13 | -0.8 ± 0.13 | -1.0 ± 0.13 | -1.3 ± 0.13 | -1.5 ± 0.14 | -0.8 ± 0.14 | -0.9 ± 0.13 | -1.0 ± 0.13 |
| Week 6 | -0.5 ± 0.14 | -0.9 ± 0.13 | -1.0 ± 0.14 | -1.4 ± 0.14 | -1.6 ± 0.14 | -0.8 ± 0.14 | -1.0 ± 0.13 | -1.2 ± 0.14 |
| Week 7 | -0.5 ± 0.14 | -0.9 ± 0.14 | -1.1 ± 0.14 | -1.4 ± 0.14 | -1.6 ± 0.15 | -1.0 ± 0.14 | -1.0 ± 0.14 | -1.2 ± 0.14 |
| Week 8 | -0.7 ± 0.15 | -1.0 ± 0.14 | -1.2 ± 0.15 | -1.5 ± 0.15 | -1.6 ± 0.15 | -0.9 ± 0.15 | -1.1 ± 0.15 | -1.3 ± 0.15 |
| Week 9 | -0.8 ± 0.15 | -1.1 ± 0.14 | -1.1 ± 0.15 | -1.6 ± 0.15 | -1.6 ± 0.15 | -0.9 ± 0.15 | -1.2 ± 0.15 | -1.3 ± 0.15 |
| Week 10 | -0.7 ± 0.15 | -1.2 ± 0.14 | -1.1 ± 0.15 | -1.5 ± 0.15 | -1.7 ± 0.15 | -1.0 ± 0.15 | -1.2 ± 0.14 | -1.4 ± 0.15 |
| Week 11 | -0.7 ± 0.15 | -1.1 ± 0.14 | -1.1 ± 0.15 | -1.6 ± 0.15 | -1.8 ± 0.15 | -1.0 ± 0.15 | -1.2 ± 0.15 | -1.4 ± 0.15 |
| Week 12 | -0.8 ± 0.15 | -1.2 ± 0.15 | -1.3 ± 0.15 | -1.6 ± 0.15 | -1.6 ± 0.16 | -1.0 ± 0.15 | -1.3 ± 0.15 | -1.3 ± 0.15 |
| Week 13 | -0.1 ± 0.10 | -0.5 ± 0.09 | -0.3 ± 0.09 | -0.4 ± 0.09 | -0.3 ± 0.09 | -0.5 ± 0.10 | -0.4 ± 0.09 | -0.2 ± 0.09 |
| Week 14 | -0.1 ± 0.10 | -0.3 ± 0.08 | -0.2 ± 0.09 | -0.3 ± 0.09 | -0.1 ± 0.09 | -0.4 ± 0.09 | -0.3 ± 0.09 | -0.2 ± 0.09 |
| Week 15 | 0.0 ± 0.10 | -0.2 ± 0.09 | -0.2 ± 0.09 | -0.4 ± 0.10 | -0.1 ± 0.09 | -0.5 ± 0.10 | -0.3 ± 0.10 | -0.1 ± 0.09 |
Severity of moderate to severe VMS per day was calculated as follows: \[(number of moderate VMS × 2) + (number of severe VMS × 3)\]/number of daily moderate/severe VMS. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Severity was zero for patients that had no moderate or severe VMS. Higher score indicates greater severity.
| Score on a scale | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Week 1 | -0.1 ± 0.10 | -0.4 ± 0.09 | -0.5 ± 0.10 | -0.6 ± 0.10 | -0.8 ± 0.10 | -0.1 ± 0.10 | -0.4 ± 0.09 | -0.4 ± 0.10 |
| Week 2 | -0.2 ± 0.12 | -0.5 ± 0.12 | -0.7 ± 0.12 | -1.0 ± 0.12 | -1.2 ± 0.13 | -0.3 ± 0.13 | -0.6 ± 0.12 | -0.8 ± 0.12 |
| Week 3 | -0.2 ± 0.14 | -0.7 ± 0.14 | -1.0 ± 0.14 | -1.2 ± 0.14 | -1.3 ± 0.15 | -0.6 ± 0.14 | -0.8 ± 0.14 | -1.0 ± 0.14 |
| Week 5 | -0.5 ± 0.15 | -0.8 ± 0.14 | -1.1 ± 0.15 | -1.4 ± 0.15 | -1.6 ± 0.15 | -0.9 ± 0.15 | -0.8 ± 0.14 | -1.1 ± 0.15 |
| Week 6 | -0.5 ± 0.15 | -0.9 ± 0.15 | -1.1 ± 0.15 | -1.5 ± 0.15 | -1.6 ± 0.16 | -0.9 ± 0.15 | -1.0 ± 0.15 | -1.3 ± 0.15 |
| Week 7 | -0.5 ± 0.15 | -0.9 ± 0.15 | -1.2 ± 0.15 | -1.5 ± 0.15 | -1.7 ± 0.16 | -1.0 ± 0.16 | -1.0 ± 0.15 | -1.2 ± 0.15 |
| Week 8 | -0.7 ± 0.16 | -1.0 ± 0.15 | -1.2 ± 0.16 | -1.6 ± 0.16 | -1.6 ± 0.17 | -0.9 ± 0.16 | -1.2 ± 0.16 | -1.3 ± 0.16 |
| Week 9 | -0.8 ± 0.16 | -1.1 ± 0.15 | -1.2 ± 0.16 | -1.6 ± 0.16 | -1.7 ± 0.16 | -0.9 ± 0.16 | -1.2 ± 0.15 | -1.3 ± 0.16 |
| Week 10 | -0.8 ± 0.16 | -1.2 ± 0.15 | -1.2 ± 0.16 | -1.7 ± 0.16 | -1.8 ± 0.16 | -1.1 ± 0.16 | -1.2 ± 0.15 | -1.4 ± 0.16 |
| Week 11 | -0.8 ± 0.16 | -1.1 ± 0.15 | -1.2 ± 0.16 | -1.7 ± 0.16 | -1.8 ± 0.16 | -1.1 ± 0.16 | -1.3 ± 0.15 | -1.5 ± 0.16 |
| Week 13 | -0.1 ± 0.13 | -0.5 ± 0.12 | -0.3 ± 0.12 | -0.6 ± 0.13 | -0.3 ± 0.13 | -0.6 ± 0.13 | -0.4 ± 0.13 | -0.2 ± 0.12 |
| Week 14 | -0.1 ± 0.13 | -0.3 ± 0.11 | -0.3 ± 0.11 | -0.5 ± 0.12 | -0.1 ± 0.12 | -0.5 ± 0.13 | -0.3 ± 0.13 | -0.2 ± 0.12 |
| Week 15 | 0.0 ± 0.13 | -0.2 ± 0.12 | -0.3 ± 0.12 | -0.6 ± 0.13 | -0.1 ± 0.13 | -0.5 ± 0.13 | -0.4 ± 0.13 | -0.1 ± 0.12 |
The hot flash score per 24h (or 12 h day time or 12 h night time) of VMS (mild, moderate, and severe) is calculated as follows: (number of mild VMS x 1) + (number of moderate VMS x 2) + (number of severe VMS x 3). Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant did not wake up but later noticed damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). Higher score indicates greater severity.
| Score on a scale | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Week 1 | -5.0 ± 1.48 | -9.8 ± 1.39 | -12.9 ± 1.45 | -14.1 ± 1.42 | -15.5 ± 1.50 | -8.4 ± 1.50 | -11.9 ± 1.39 | -11.9 ± 1.45 |
| Week 2 | -8.9 ± 1.50 | -13.0 ± 1.41 | -16.5 ± 1.47 | -17.0 ± 1.44 | -18.1 ± 1.52 | -13.5 ± 1.52 | -14.8 ± 1.41 | -14.5 ± 1.47 |
| Week 3 | -8.9 ± 1.54 | -14.5 ± 1.45 | -17.6 ± 1.51 | -17.7 ± 1.48 | -19.1 ± 1.57 | -15.4 ± 1.56 | -16.6 ± 1.45 | -15.9 ± 1.51 |
| Week 4 | -9.5 ± 1.53 | -14.9 ± 1.45 | -17.9 ± 1.51 | -17.6 ± 1.47 | -19.7 ± 1.57 | -15.9 ± 1.56 | -17.7 ± 1.45 | -17.1 ± 1.51 |
| Week 5 | -10.6 ± 1.45 | -15.4 ± 1.37 | -18.4 ± 1.43 | -18.6 ± 1.40 | -20.5 ± 1.49 | -16.9 ± 1.48 | -17.8 ± 1.37 | -17.2 ± 1.44 |
| Week 6 | -11.6 ± 1.44 | -16.4 ± 1.36 | -18.4 ± 1.42 | -19.4 ± 1.39 | -20.6 ± 1.48 | -16.9 ± 1.47 | -18.2 ± 1.36 | -18.1 ± 1.43 |
| Week 7 | -11.8 ± 1.46 | -16.2 ± 1.38 | -18.9 ± 1.44 | -19.1 ± 1.41 | -20.9 ± 1.50 | -17.4 ± 1.49 | -18.2 ± 1.39 | -18.3 ± 1.45 |
| Week 8 | -13.0 ± 1.46 | -16.3 ± 1.38 | -18.9 ± 1.44 | -19.5 ± 1.42 | -20.5 ± 1.51 | -17.4 ± 1.50 | -18.8 ± 1.39 | -18.7 ± 1.45 |
| Week 9 | -13.6 ± 1.40 | -17.6 ± 1.32 | -19.0 ± 1.37 | -20.2 ± 1.36 | -20.9 ± 1.44 | -17.3 ± 1.43 | -19.3 ± 1.33 | -18.7 ± 1.39 |
| Week 10 | -13.1 ± 1.44 | -17.9 ± 1.37 | -18.5 ± 1.42 | -20.1 ± 1.41 | -20.8 ± 1.49 | -18.2 ± 1.48 | -19.4 ± 1.38 | -19.1 ± 1.44 |
| Week 11 | -13.2 ± 1.41 | -17.9 ± 1.33 | -19.2 ± 1.39 | -20.9 ± 1.38 | -20.8 ± 1.46 | -18.6 ± 1.45 | -19.9 ± 1.35 | -19.2 ± 1.41 |
| Week 12 | -13.1 ± 1.38 | -18.2 ± 1.31 | -19.2 ± 1.36 | -20.7 ± 1.35 | -21.3 ± 1.43 | -18.7 ± 1.42 | -19.8 ± 1.32 | -19.4 ± 1.38 |
| Week 13 | -10.7 ± 1.63 | -16.0 ± 1.46 | -13.6 ± 1.51 | -12.7 ± 1.57 | -14.4 ± 1.61 | -16.3 ± 1.62 | -15.3 ± 1.56 | -13.3 ± 1.54 |
| Week 14 | -10.0 ± 1.66 | -14.1 ± 1.50 | -11.5 ± 1.53 | -11.5 ± 1.63 | -12.5 ± 1.66 | -15.3 ± 1.67 | -14.7 ± 1.62 | -12.3 ± 1.57 |
| Week 15 | -11.0 ± 1.59 | -12.3 ± 1.46 | -11.7 ± 1.48 | -10.8 ± 1.61 | -11.0 ± 1.60 | -13.6 ± 1.65 | -14.2 ± 1.59 | -10.9 ± 1.51 |
The hot flash score per 24h of moderate and severe VMS is calculated as follows: (number of moderate VMS x 2) + (number of severe VMS x 3). Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed). VMS. Baseline is the average frequency of 24h vasomotor symptom from 7 non-missing days prior to Day 1. Higher score indicates greater severity.
| Score on a scale | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Week 1 | -5.1 ± 1.49 | -10.2 ± 1.40 | -13.4 ± 1.46 | -14.3 ± 1.43 | -15.7 ± 1.51 | -8.8 ± 1.51 | -12.2 ± 1.40 | -11.8 ± 1.46 |
| Week 2 | -8.9 ± 1.51 | -13.5 ± 1.41 | -17.0 ± 1.48 | -16.9 ± 1.44 | -18.2 ± 1.53 | -13.8 ± 1.53 | -15.5 ± 1.42 | -14.3 ± 1.48 |
| Week 3 | -8.9 ± 1.54 | -14.8 ± 1.45 | -18.2 ± 1.52 | -17.5 ± 1.48 | -19.1 ± 1.57 | -15.9 ± 1.57 | -17.3 ± 1.46 | -15.6 ± 1.52 |
| Week 4 | -9.5 ± 1.54 | -15.2 ± 1.46 | -18.3 ± 1.51 | -17.4 ± 1.48 | -19.6 ± 1.57 | -16.4 ± 1.56 | -18.0 ± 1.45 | -16.7 ± 1.51 |
| Week 5 | -10.5 ± 1.46 | -15.8 ± 1.38 | -18.8 ± 1.44 | -18.3 ± 1.41 | -20.3 ± 1.50 | -17.2 ± 1.49 | -18.2 ± 1.38 | -16.8 ± 1.45 |
| Week 6 | -11.5 ± 1.45 | -16.7 ± 1.37 | -18.7 ± 1.43 | -19.0 ± 1.40 | -20.3 ± 1.49 | -17.3 ± 1.48 | -18.6 ± 1.37 | -17.6 ± 1.44 |
| Week 7 | -11.8 ± 1.47 | -16.6 ± 1.39 | -19.2 ± 1.45 | -18.7 ± 1.42 | -20.6 ± 1.51 | -17.7 ± 1.50 | -18.5 ± 1.39 | -17.8 ± 1.46 |
| Week 8 | -13.0 ± 1.47 | -16.6 ± 1.38 | -19.1 ± 1.44 | -19.1 ± 1.42 | -20.2 ± 1.51 | -17.7 ± 1.50 | -19.0 ± 1.39 | -18.2 ± 1.46 |
| Week 9 | -13.5 ± 1.41 | -17.9 ± 1.33 | -19.3 ± 1.38 | -19.8 ± 1.37 | -20.5 ± 1.45 | -17.7 ± 1.44 | -19.4 ± 1.34 | -18.2 ± 1.40 |
| Week 10 | -12.9 ± 1.45 | -18.2 ± 1.37 | -18.9 ± 1.42 | -19.7 ± 1.41 | -20.4 ± 1.49 | -18.4 ± 1.48 | -19.5 ± 1.38 | -18.7 ± 1.44 |
| Week 11 | -13.0 ± 1.42 | -18.2 ± 1.34 | -19.4 ± 1.39 | -20.5 ± 1.38 | -20.5 ± 1.46 | -18.9 ± 1.45 | -19.9 ± 1.35 | -18.8 ± 1.41 |
| Week 12 | -12.8 ± 1.39 | -18.4 ± 1.31 | -19.3 ± 1.36 | -20.3 ± 1.36 | -21.0 ± 1.43 | -19.0 ± 1.42 | -19.8 ± 1.32 | -19.0 ± 1.38 |
| Week 13 | -10.4 ± 1.65 | -16.4 ± 1.49 | -13.8 ± 1.54 | -13.1 ± 1.60 | -14.4 ± 1.64 | -17.0 ± 1.65 | -15.4 ± 1.59 | -13.0 ± 1.56 |
| Week 14 | -9.7 ± 1.70 | -14.5 ± 1.53 | -11.5 ± 1.57 | -11.7 ± 1.66 | -12.5 ± 1.69 | -15.9 ± 1.70 | -14.6 ± 1.66 | -12.0 ± 1.60 |
| Week 15 | -10.7 ± 1.65 | -12.9 ± 1.51 | -11.6 ± 1.53 | -11.1 ± 1.67 | -10.9 ± 1.66 | -14.7 ± 1.71 | -14.1 ± 1.65 | -10.6 ± 1.56 |
The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, subject does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
| Percent Reduction | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Week 1 | 14.5 ± 5.33 | 29.1 ± 5.01 | 37.6 ± 5.21 | 51.8 ± 5.12 | 55.5 ± 5.39 | 22.7 ± 5.40 | 40.1 ± 5.02 | 44.7 ± 5.22 |
| Week 2 | 30.3 ± 5.30 | 46.2 ± 4.99 | 54.8 ± 5.20 | 64.0 ± 5.09 | 68.3 ± 5.39 | 44.8 ± 5.38 | 49.8 ± 5.01 | 56.1 ± 5.21 |
| Week 3 | 32.0 ± 5.66 | 52.2 ± 5.37 | 60.3 ± 5.58 | 68.9 ± 5.44 | 72.5 ± 5.77 | 51.7 ± 5.75 | 56.9 ± 5.37 | 62.8 ± 5.56 |
| Week 4 | 34.7 ± 5.58 | 55.3 ± 5.33 | 63.5 ± 5.52 | 68.1 ± 5.39 | 76.2 ± 5.72 | 54.5 ± 5.69 | 64.7 ± 5.30 | 67.9 ± 5.50 |
| Week 5 | 41.3 ± 5.32 | 56.7 ± 5.08 | 66.1 ± 5.26 | 72.1 ± 5.17 | 80.1 ± 5.49 | 60.4 ± 5.42 | 63.6 ± 5.06 | 66.4 ± 5.28 |
| Week 6 | 45.4 ± 5.01 | 60.0 ± 4.74 | 65.3 ± 4.93 | 75.1 ± 4.86 | 81.1 ± 5.16 | 60.1 ± 5.12 | 65.9 ± 4.75 | 72.0 ± 4.97 |
| Week 7 | 45.1 ± 5.17 | 59.6 ± 4.92 | 68.1 ± 5.10 | 74.0 ± 5.05 | 81.9 ± 5.34 | 60.7 ± 5.29 | 66.3 ± 4.93 | 72.2 ± 5.14 |
| Week 8 | 50.9 ± 5.13 | 60.5 ± 4.87 | 69.0 ± 5.05 | 76.1 ± 5.01 | 81.5 ± 5.32 | 62.1 ± 5.26 | 69.2 ± 4.90 | 74.5 ± 5.11 |
| Week 9 | 53.8 ± 4.90 | 65.7 ± 4.64 | 68.4 ± 4.81 | 78.2 ± 4.78 | 83.4 ± 5.06 | 62.2 ± 5.03 | 72.3 ± 4.67 | 74.5 ± 4.88 |
| Week 10 | 51.8 ± 5.03 | 67.6 ± 4.78 | 64.6 ± 4.95 | 77.6 ± 4.95 | 83.4 ± 5.20 | 66.1 ± 5.17 | 73.0 ± 4.82 | 76.2 ± 5.02 |
| Week 11 | 53.5 ± 4.88 | 68.0 ± 4.63 | 68.8 ± 4.81 | 80.0 ± 4.81 | 83.4 ± 5.05 | 67.4 ± 5.02 | 75.4 ± 4.66 | 76.9 ± 4.87 |
| Week 12 | 53.2 ± 4.87 | 68.0 ± 4.62 | 70.2 ± 4.80 | 79.6 ± 4.80 | 84.2 ± 5.04 | 68.0 ± 5.01 | 75.1 ± 4.65 | 76.4 ± 4.86 |
| Week 13 | 43.6 ± 5.69 | 53.3 ± 5.07 | 45.9 ± 5.24 | 45.1 ± 5.47 | 50.7 ± 5.59 | 49.3 ± 5.66 | 54.0 ± 5.44 | 48.0 ± 5.32 |
| Week 14 | 39.9 ± 6.12 | 42.0 ± 5.50 | 41.2 ± 5.60 | 39.6 ± 5.99 | 43.8 ± 6.08 | 41.5 ± 6.14 | 52.9 ± 6.01 | 47.0 ± 5.72 |
| Week 15 | 45.0 ± 5.97 | 37.1 ± 5.49 | 42.9 ± 5.56 | 37.8 ± 6.06 | 39.4 ± 6.01 | 32.4 ± 6.21 | 51.4 ± 6.00 | 43.0 ± 5.64 |
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
| Percent Reduction | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Week 1 | 17.5 ± 5.51 | 36.6 ± 5.18 | 44.5 ± 5.39 | 57.0 ± 5.30 | 62.3 ± 5.57 | 29.6 ± 5.59 | 45.3 ± 5.20 | 47.0 ± 5.40 |
| Week 2 | 33.8 ± 5.34 | 53.7 ± 5.01 | 62.4 ± 5.23 | 67.6 ± 5.12 | 73.3 ± 5.42 | 51.4 ± 5.41 | 57.9 ± 5.03 | 57.7 ± 5.25 |
| Week 3 | 34.8 ± 5.61 | 58.1 ± 5.31 | 69.2 ± 5.53 | 70.5 ± 5.40 | 77.8 ± 5.73 | 60.3 ± 5.71 | 66.0 ± 5.32 | 63.7 ± 5.52 |
| Week 4 | 38.6 ± 5.57 | 61.7 ± 5.31 | 70.7 ± 5.50 | 70.0 ± 5.37 | 80.5 ± 5.71 | 64.2 ± 5.68 | 70.0 ± 5.28 | 68.1 ± 5.49 |
| Week 5 | 43.6 ± 5.31 | 63.8 ± 5.06 | 74.2 ± 5.25 | 72.7 ± 5.17 | 83.7 ± 5.49 | 68.0 ± 5.42 | 70.3 ± 5.04 | 67.0 ± 5.28 |
| Week 6 | 48.5 ± 5.02 | 67.7 ± 4.75 | 72.4 ± 4.94 | 75.7 ± 4.87 | 84.1 ± 5.19 | 68.5 ± 5.14 | 72.6 ± 4.76 | 71.7 ± 4.99 |
| Week 7 | 49.1 ± 5.16 | 66.7 ± 4.90 | 74.9 ± 5.09 | 74.9 ± 5.04 | 85.4 ± 5.34 | 69.7 ± 5.28 | 72.0 ± 4.91 | 71.9 ± 5.14 |
| Week 8 | 54.5 ± 5.09 | 68.3 ± 4.81 | 74.5 ± 5.01 | 76.6 ± 4.96 | 84.5 ± 5.28 | 69.4 ± 5.23 | 74.1 ± 4.85 | 74.1 ± 5.08 |
| Week 9 | 56.4 ± 4.91 | 72.4 ± 4.64 | 74.5 ± 4.82 | 79.0 ± 4.78 | 85.7 ± 5.08 | 70.1 ± 5.05 | 76.5 ± 4.68 | 73.8 ± 4.90 |
| Week 10 | 53.5 ± 5.03 | 74.2 ± 4.77 | 72.3 ± 4.95 | 77.9 ± 4.95 | 85.6 ± 5.21 | 72.6 ± 5.18 | 76.6 ± 4.81 | 76.4 ± 5.03 |
| Week 11 | 55.6 ± 4.82 | 74.1 ± 4.55 | 75.8 ± 4.75 | 80.6 ± 4.73 | 85.4 ± 4.99 | 75.1 ± 4.96 | 79.0 ± 4.59 | 77.3 ± 4.82 |
| Week 12 | 55.0 ± 4.85 | 74.3 ± 4.58 | 75.8 ± 4.77 | 80.2 ± 4.77 | 86.9 ± 5.02 | 75.1 ± 4.99 | 77.7 ± 4.61 | 76.9 ± 4.84 |
| Week 13 | 44.9 ± 6.02 | 61.9 ± 5.37 | 51.7 ± 5.55 | 52.5 ± 5.78 | 55.8 ± 5.92 | 61.3 ± 5.98 | 56.6 ± 5.76 | 48.8 ± 5.63 |
| Week 14 | 41.0 ± 6.47 | 50.4 ± 5.83 | 44.9 ± 5.93 | 45.9 ± 6.34 | 47.2 ± 6.44 | 51.4 ± 6.49 | 55.3 ± 6.36 | 47.7 ± 6.06 |
| Week 15 | 45.6 ± 6.49 | 44.7 ± 5.98 | 45.6 ± 6.04 | 46.0 ± 6.61 | 41.7 ± 6.54 | 45.5 ± 6.76 | 53.2 ± 6.57 | 42.9 ± 6.12 |
The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
| participants | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Week 1 | 5 | 19 | 22 | 24 | 25 | 10 | 21 | 23 |
| Week 2 | 14 | 26 | 29 | 32 | 30 | 22 | 26 | 28 |
| Week 3 | 16 | 26 | 29 | 33 | 32 | 26 | 29 | 29 |
| Week 4 | 19 | 26 | 29 | 31 | 31 | 25 | 32 | 31 |
| Week 5 | 22 | 24 | 31 | 30 | 29 | 28 | 30 | 29 |
| Week 6 | 24 | 24 | 30 | 31 | 28 | 24 | 30 | 33 |
| Week 7 | 25 | 25 | 32 | 29 | 28 | 28 | 30 | 30 |
| Week 8 | 26 | 28 | 32 | 32 | 28 | 25 | 31 | 32 |
| Week 9 | 27 | 29 | 33 | 31 | 31 | 25 | 30 | 31 |
| Week 10 | 23 | 28 | 26 | 26 | 31 | 26 | 32 | 32 |
| Week 11 | 23 | 28 | 30 | 25 | 30 | 27 | 33 | 31 |
| Week 12 | 21 | 27 | 27 | 27 | 28 | 24 | 32 | 32 |
| Week 13 | 12 | 19 | 17 | 14 | 15 | 16 | 14 | 17 |
| Week 14 | 11 | 14 | 15 | 10 | 13 | 15 | 14 | 17 |
| Week 15 | 14 | 10 | 12 | 6 | 9 | 9 | 12 | 13 |
The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
| participants | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Week 1 | 2 | 6 | 11 | 17 | 18 | 6 | 7 | 16 |
| Week 2 | 9 | 15 | 19 | 26 | 24 | 13 | 13 | 21 |
| Week 3 | 11 | 17 | 20 | 27 | 27 | 17 | 16 | 26 |
| Week 4 | 10 | 14 | 22 | 24 | 30 | 19 | 24 | 26 |
| Week 5 | 15 | 17 | 21 | 26 | 29 | 22 | 22 | 25 |
| Week 6 | 14 | 18 | 21 | 27 | 28 | 19 | 22 | 26 |
| Week 7 | 15 | 19 | 24 | 25 | 28 | 20 | 22 | 25 |
| Week 8 | 18 | 19 | 25 | 24 | 27 | 19 | 21 | 26 |
| Week 9 | 18 | 21 | 22 | 27 | 28 | 19 | 24 | 26 |
| Week 10 | 16 | 21 | 20 | 23 | 29 | 21 | 26 | 24 |
| Week 11 | 19 | 25 | 23 | 24 | 28 | 20 | 28 | 28 |
| Week 12 | 18 | 21 | 22 | 25 | 26 | 22 | 26 | 27 |
| Week 13 | 4 | 12 | 7 | 9 | 7 | 10 | 5 | 11 |
| Week 14 | 8 | 6 | 5 | 3 | 2 | 7 | 7 | 10 |
| Week 15 | 8 | 4 | 5 | 3 | 0 | 2 | 5 | 7 |
The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
| participants | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Week 1 | 1 | 1 | 1 | 6 | 6 | 0 | 3 | 2 |
| Week 2 | 2 | 5 | 6 | 15 | 16 | 2 | 5 | 12 |
| Week 3 | 4 | 9 | 9 | 19 | 16 | 6 | 9 | 17 |
| Week 4 | 6 | 10 | 12 | 19 | 17 | 7 | 12 | 18 |
| Week 5 | 6 | 7 | 11 | 18 | 20 | 9 | 10 | 18 |
| Week 6 | 9 | 9 | 16 | 21 | 23 | 9 | 9 | 21 |
| Week 7 | 6 | 8 | 15 | 20 | 24 | 10 | 12 | 20 |
| Week 8 | 13 | 11 | 17 | 22 | 23 | 10 | 14 | 22 |
| Week 9 | 13 | 11 | 15 | 21 | 25 | 10 | 14 | 20 |
| Week 10 | 13 | 12 | 14 | 20 | 26 | 11 | 15 | 20 |
| Week 11 | 14 | 13 | 13 | 19 | 25 | 12 | 18 | 20 |
| Week 12 | 13 | 15 | 15 | 17 | 22 | 10 | 16 | 20 |
| Week 13 | 1 | 0 | 1 | 2 | 1 | 3 | 1 | 2 |
| Week 14 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 1 |
| Week 15 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
| participants | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Week 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Week 2 | 1 | 2 | 0 | 5 | 7 | 0 | 3 | 4 |
| Week 3 | 1 | 3 | 3 | 9 | 8 | 2 | 4 | 9 |
| Week 4 | 1 | 2 | 4 | 6 | 11 | 3 | 6 | 8 |
| Week 5 | 3 | 2 | 3 | 10 | 10 | 3 | 6 | 6 |
| Week 6 | 1 | 6 | 3 | 11 | 13 | 3 | 5 | 12 |
| Week 7 | 1 | 5 | 5 | 13 | 11 | 6 | 6 | 14 |
| Week 8 | 2 | 7 | 7 | 15 | 12 | 5 | 6 | 14 |
| Week 9 | 3 | 7 | 11 | 12 | 15 | 3 | 7 | 12 |
| Week 10 | 4 | 7 | 6 | 9 | 16 | 3 | 8 | 15 |
| Week 11 | 3 | 7 | 7 | 13 | 17 | 7 | 8 | 13 |
| Week 12 | 8 | 7 | 10 | 11 | 14 | 5 | 12 | 10 |
| Week 13 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Week 14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
| participants | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Week 1 | 6 | 21 | 25 | 27 | 28 | 14 | 23 | 25 |
| Week 2 | 15 | 31 | 31 | 32 | 32 | 25 | 29 | 27 |
| Week 3 | 18 | 31 | 31 | 33 | 33 | 30 | 33 | 29 |
| Week 4 | 23 | 29 | 31 | 32 | 32 | 29 | 32 | 31 |
| Week 5 | 23 | 30 | 34 | 29 | 31 | 32 | 35 | 30 |
| Week 6 | 25 | 29 | 31 | 31 | 30 | 28 | 34 | 32 |
| Week 7 | 26 | 29 | 33 | 30 | 30 | 31 | 32 | 29 |
| Week 8 | 28 | 31 | 33 | 32 | 28 | 30 | 33 | 32 |
| Week 9 | 27 | 30 | 33 | 32 | 31 | 28 | 32 | 29 |
| Week 10 | 25 | 31 | 29 | 26 | 31 | 29 | 35 | 31 |
| Week 11 | 25 | 31 | 31 | 25 | 30 | 31 | 34 | 31 |
| Week 12 | 22 | 31 | 29 | 27 | 29 | 26 | 32 | 31 |
| Week 13 | 12 | 22 | 18 | 14 | 18 | 19 | 16 | 16 |
| Week 14 | 11 | 19 | 16 | 9 | 14 | 18 | 14 | 18 |
| Week 15 | 13 | 12 | 12 | 8 | 12 | 14 | 12 | 13 |
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
| participants | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Week 1 | 2 | 11 | 14 | 21 | 22 | 6 | 11 | 17 |
| Week 2 | 9 | 18 | 25 | 27 | 25 | 15 | 20 | 22 |
| Week 3 | 11 | 22 | 27 | 28 | 28 | 21 | 24 | 25 |
| Week 4 | 13 | 20 | 29 | 25 | 30 | 25 | 28 | 25 |
| Week 5 | 16 | 20 | 30 | 25 | 29 | 25 | 28 | 26 |
| Week 6 | 18 | 21 | 29 | 27 | 28 | 23 | 30 | 26 |
| Week 7 | 18 | 23 | 32 | 25 | 28 | 25 | 28 | 25 |
| Week 8 | 19 | 26 | 31 | 26 | 28 | 21 | 26 | 26 |
| Week 9 | 21 | 26 | 29 | 27 | 29 | 25 | 28 | 26 |
| Week 10 | 18 | 26 | 28 | 23 | 29 | 23 | 29 | 25 |
| Week 11 | 21 | 27 | 30 | 24 | 28 | 26 | 30 | 28 |
| Week 12 | 20 | 24 | 27 | 24 | 27 | 25 | 28 | 26 |
| Week 13 | 5 | 17 | 9 | 11 | 8 | 15 | 7 | 12 |
| Week 14 | 9 | 10 | 8 | 7 | 3 | 10 | 7 | 10 |
| Week 15 | 7 | 9 | 8 | 4 | 1 | 8 | 7 | 8 |
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
| participants | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Week 1 | 1 | 4 | 5 | 10 | 12 | 2 | 4 | 6 |
| Week 2 | 3 | 8 | 13 | 18 | 21 | 7 | 7 | 14 |
| Week 3 | 5 | 12 | 15 | 23 | 23 | 9 | 14 | 18 |
| Week 4 | 8 | 12 | 18 | 23 | 22 | 12 | 14 | 18 |
| Week 5 | 8 | 12 | 18 | 20 | 24 | 13 | 13 | 19 |
| Week 6 | 10 | 13 | 21 | 22 | 25 | 12 | 14 | 21 |
| Week 7 | 9 | 12 | 22 | 21 | 26 | 12 | 17 | 21 |
| Week 8 | 14 | 17 | 22 | 22 | 27 | 12 | 19 | 22 |
| Week 9 | 16 | 17 | 22 | 24 | 27 | 12 | 20 | 21 |
| Week 10 | 14 | 18 | 19 | 20 | 28 | 16 | 18 | 22 |
| Week 11 | 15 | 18 | 20 | 20 | 26 | 16 | 21 | 21 |
| Week 12 | 14 | 18 | 19 | 18 | 24 | 16 | 19 | 22 |
| Week 13 | 1 | 5 | 3 | 9 | 2 | 8 | 3 | 2 |
| Week 14 | 1 | 4 | 3 | 4 | 1 | 5 | 3 | 1 |
| Week 15 | 0 | 2 | 3 | 3 | 0 | 1 | 4 | 1 |
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
| participants | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Week 1 | 1 | 1 | 0 | 3 | 3 | 0 | 1 | 0 |
| Week 2 | 1 | 2 | 3 | 7 | 10 | 0 | 4 | 6 |
| Week 3 | 1 | 5 | 6 | 9 | 12 | 4 | 6 | 12 |
| Week 4 | 1 | 3 | 8 | 10 | 14 | 4 | 8 | 9 |
| Week 5 | 4 | 5 | 8 | 10 | 15 | 6 | 7 | 8 |
| Week 6 | 1 | 8 | 10 | 12 | 16 | 5 | 6 | 15 |
| Week 7 | 1 | 7 | 10 | 14 | 16 | 9 | 10 | 15 |
| Week 8 | 4 | 9 | 12 | 16 | 16 | 6 | 9 | 15 |
| Week 9 | 5 | 9 | 12 | 15 | 18 | 5 | 12 | 15 |
| Week 10 | 7 | 9 | 11 | 16 | 19 | 6 | 9 | 17 |
| Week 11 | 5 | 9 | 11 | 15 | 19 | 10 | 9 | 15 |
| Week 12 | 9 | 8 | 12 | 14 | 16 | 9 | 14 | 13 |
| Week 13 | 0 | 1 | 2 | 6 | 1 | 3 | 1 | 1 |
| Week 14 | 1 | 1 | 2 | 2 | 0 | 2 | 1 | 0 |
| Week 15 | 0 | 1 | 2 | 3 | 0 | 1 | 1 | 0 |
The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
| participants | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Week 1 | 20 | 27 | 32 | 35 | 33 | 23 | 34 | 32 |
| Week 2 | 28 | 34 | 32 | 38 | 33 | 32 | 36 | 33 |
| Week 3 | 29 | 33 | 35 | 37 | 35 | 34 | 35 | 39 |
| Week 4 | 30 | 31 | 34 | 35 | 35 | 33 | 40 | 39 |
| Week 5 | 33 | 34 | 38 | 33 | 34 | 36 | 38 | 36 |
| Week 6 | 33 | 36 | 37 | 33 | 33 | 33 | 37 | 39 |
| Week 7 | 32 | 34 | 36 | 32 | 33 | 32 | 37 | 38 |
| Week 8 | 34 | 35 | 36 | 34 | 32 | 33 | 37 | 37 |
| Week 9 | 33 | 34 | 37 | 33 | 33 | 32 | 37 | 37 |
| Week 10 | 34 | 34 | 32 | 29 | 33 | 33 | 36 | 36 |
| Week 11 | 34 | 33 | 34 | 27 | 31 | 33 | 36 | 36 |
| Week 12 | 31 | 34 | 31 | 28 | 31 | 31 | 35 | 35 |
| Week 13 | 17 | 30 | 26 | 22 | 22 | 21 | 25 | 28 |
| Week 14 | 17 | 22 | 26 | 16 | 21 | 20 | 21 | 25 |
| Week 15 | 18 | 18 | 20 | 12 | 20 | 12 | 16 | 22 |
The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
| participants | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Week 1 | 14 | 23 | 29 | 32 | 28 | 18 | 31 | 29 |
| Week 2 | 19 | 30 | 30 | 36 | 32 | 28 | 33 | 31 |
| Week 3 | 24 | 31 | 30 | 36 | 34 | 29 | 34 | 32 |
| Week 4 | 26 | 30 | 32 | 34 | 34 | 29 | 35 | 34 |
| Week 5 | 29 | 31 | 36 | 33 | 33 | 34 | 35 | 33 |
| Week 6 | 28 | 29 | 33 | 31 | 32 | 30 | 36 | 38 |
| Week 7 | 30 | 31 | 34 | 30 | 32 | 31 | 37 | 38 |
| Week 8 | 31 | 32 | 34 | 32 | 29 | 31 | 37 | 34 |
| Week 9 | 30 | 32 | 33 | 32 | 32 | 31 | 36 | 34 |
| Week 10 | 29 | 32 | 29 | 29 | 31 | 31 | 36 | 34 |
| Week 11 | 30 | 31 | 30 | 27 | 30 | 32 | 36 | 34 |
| Week 12 | 28 | 31 | 31 | 27 | 28 | 30 | 34 | 33 |
| Week 13 | 16 | 24 | 20 | 21 | 18 | 20 | 19 | 26 |
| Week 14 | 15 | 18 | 21 | 15 | 17 | 17 | 18 | 23 |
| Week 15 | 17 | 15 | 18 | 12 | 13 | 11 | 14 | 17 |
The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
| participants | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Week 1 | 8 | 21 | 21 | 26 | 24 | 16 | 22 | 29 |
| Week 2 | 16 | 27 | 29 | 33 | 28 | 25 | 27 | 26 |
| Week 3 | 18 | 28 | 27 | 33 | 31 | 26 | 33 | 31 |
| Week 4 | 22 | 27 | 28 | 31 | 30 | 26 | 32 | 31 |
| Week 5 | 24 | 28 | 31 | 30 | 33 | 28 | 34 | 31 |
| Week 6 | 27 | 28 | 27 | 31 | 30 | 26 | 34 | 33 |
| Week 7 | 27 | 27 | 32 | 30 | 30 | 26 | 33 | 32 |
| Week 8 | 28 | 29 | 32 | 31 | 29 | 28 | 34 | 30 |
| Week 9 | 28 | 30 | 31 | 32 | 31 | 28 | 35 | 32 |
| Week 10 | 27 | 29 | 27 | 28 | 30 | 30 | 34 | 31 |
| Week 11 | 27 | 28 | 28 | 26 | 30 | 30 | 35 | 31 |
| Week 12 | 25 | 26 | 28 | 27 | 27 | 27 | 33 | 32 |
| Week 13 | 12 | 20 | 16 | 18 | 17 | 18 | 17 | 23 |
| Week 14 | 14 | 16 | 17 | 12 | 13 | 16 | 15 | 18 |
| Week 15 | 15 | 14 | 13 | 9 | 12 | 10 | 12 | 13 |
The frequency of mild, moderate and severe VMS was the number of mild, moderate and severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Mild VMS was defined as sensation of heat without sweating/dampness. If at night, participant does not wake up but later notices damp sheets or clothing. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
| participants | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Week 1 | 5 | 17 | 19 | 22 | 21 | 13 | 18 | 20 |
| Week 2 | 14 | 25 | 24 | 27 | 24 | 21 | 23 | 26 |
| Week 3 | 16 | 25 | 25 | 29 | 27 | 25 | 29 | 27 |
| Week 4 | 17 | 24 | 26 | 25 | 28 | 24 | 31 | 27 |
| Week 5 | 20 | 24 | 26 | 26 | 28 | 26 | 32 | 28 |
| Week 6 | 22 | 24 | 25 | 30 | 27 | 25 | 30 | 30 |
| Week 7 | 22 | 27 | 27 | 27 | 28 | 24 | 28 | 30 |
| Week 8 | 22 | 26 | 26 | 28 | 26 | 23 | 31 | 30 |
| Week 9 | 26 | 25 | 26 | 28 | 28 | 23 | 32 | 30 |
| Week 10 | 22 | 26 | 23 | 25 | 29 | 25 | 32 | 30 |
| Week 11 | 24 | 27 | 25 | 24 | 27 | 27 | 33 | 30 |
| Week 12 | 23 | 23 | 26 | 22 | 26 | 24 | 31 | 29 |
| Week 13 | 9 | 18 | 13 | 14 | 14 | 17 | 13 | 17 |
| Week 14 | 10 | 15 | 12 | 10 | 9 | 16 | 13 | 14 |
| Week 15 | 11 | 11 | 9 | 8 | 7 | 9 | 11 | 12 |
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
| participants | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Week 1 | 22 | 33 | 32 | 35 | 36 | 28 | 34 | 32 |
| Week 2 | 30 | 36 | 33 | 37 | 36 | 36 | 38 | 33 |
| Week 3 | 31 | 33 | 36 | 36 | 36 | 37 | 37 | 39 |
| Week 4 | 31 | 34 | 34 | 34 | 36 | 36 | 40 | 39 |
| Week 5 | 32 | 34 | 39 | 32 | 35 | 37 | 39 | 35 |
| Week 6 | 33 | 36 | 37 | 32 | 33 | 34 | 37 | 38 |
| Week 7 | 33 | 35 | 36 | 31 | 34 | 34 | 37 | 38 |
| Week 8 | 35 | 36 | 36 | 32 | 33 | 35 | 37 | 37 |
| Week 9 | 33 | 35 | 37 | 31 | 33 | 34 | 37 | 37 |
| Week 10 | 34 | 35 | 32 | 28 | 33 | 34 | 36 | 35 |
| Week 11 | 34 | 35 | 34 | 26 | 32 | 34 | 36 | 36 |
| Week 12 | 31 | 35 | 31 | 27 | 31 | 32 | 35 | 35 |
| Week 13 | 17 | 29 | 27 | 21 | 24 | 24 | 22 | 27 |
| Week 14 | 17 | 23 | 26 | 17 | 20 | 23 | 22 | 25 |
| Week 15 | 18 | 19 | 22 | 14 | 19 | 14 | 17 | 21 |
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
| participants | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Week 1 | 15 | 25 | 30 | 30 | 33 | 23 | 33 | 28 |
| Week 2 | 22 | 33 | 32 | 35 | 34 | 32 | 35 | 30 |
| Week 3 | 25 | 32 | 31 | 34 | 35 | 33 | 37 | 33 |
| Week 4 | 26 | 32 | 32 | 33 | 35 | 33 | 37 | 34 |
| Week 5 | 31 | 34 | 36 | 31 | 34 | 36 | 37 | 33 |
| Week 6 | 30 | 33 | 33 | 30 | 33 | 33 | 36 | 37 |
| Week 7 | 31 | 32 | 33 | 29 | 33 | 32 | 34 | 37 |
| Week 8 | 32 | 33 | 33 | 31 | 31 | 33 | 35 | 32 |
| Week 9 | 30 | 32 | 33 | 31 | 33 | 33 | 34 | 34 |
| Week 10 | 28 | 33 | 30 | 28 | 33 | 34 | 36 | 34 |
| Week 11 | 30 | 32 | 31 | 26 | 32 | 34 | 36 | 33 |
| Week 12 | 28 | 32 | 31 | 26 | 31 | 31 | 34 | 33 |
| Week 13 | 16 | 25 | 22 | 20 | 21 | 22 | 21 | 26 |
| Week 14 | 15 | 21 | 21 | 14 | 18 | 19 | 19 | 22 |
| Week 15 | 18 | 17 | 18 | 12 | 15 | 13 | 16 | 17 |
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
| participants | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Week 1 | 11 | 25 | 23 | 26 | 26 | 19 | 26 | 27 |
| Week 2 | 16 | 30 | 29 | 32 | 32 | 26 | 29 | 26 |
| Week 3 | 20 | 31 | 29 | 31 | 33 | 28 | 36 | 31 |
| Week 4 | 23 | 28 | 29 | 29 | 31 | 31 | 33 | 30 |
| Week 5 | 27 | 29 | 31 | 28 | 34 | 33 | 35 | 31 |
| Week 6 | 28 | 31 | 29 | 29 | 31 | 30 | 34 | 32 |
| Week 7 | 28 | 31 | 32 | 28 | 32 | 30 | 32 | 31 |
| Week 8 | 29 | 33 | 32 | 30 | 30 | 31 | 34 | 30 |
| Week 9 | 28 | 31 | 30 | 31 | 33 | 31 | 34 | 32 |
| Week 10 | 27 | 31 | 27 | 26 | 31 | 32 | 35 | 31 |
| Week 11 | 27 | 31 | 28 | 24 | 31 | 33 | 35 | 30 |
| Week 12 | 25 | 29 | 28 | 25 | 29 | 29 | 31 | 31 |
| Week 13 | 13 | 23 | 18 | 17 | 19 | 20 | 18 | 21 |
| Week 14 | 14 | 19 | 16 | 11 | 16 | 18 | 15 | 17 |
| Week 15 | 15 | 15 | 12 | 10 | 14 | 13 | 11 | 13 |
The frequency of moderate to severe VMS was the number of moderate to severe VMS per 24 hours. A daily frequency and severity per week was derived by taking the mean of the data over 7 days. Moderate VMS was defined as sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. Severe VMS was defined as sensation of intense heat with sweating, caused disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., remove layers of clothes, open the window, or get out of bed).
| participants | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Week 1 | 6 | 19 | 22 | 23 | 22 | 14 | 17 | 22 |
| Week 2 | 14 | 25 | 27 | 27 | 25 | 24 | 27 | 24 |
| Week 3 | 16 | 25 | 27 | 28 | 28 | 25 | 31 | 25 |
| Week 4 | 19 | 24 | 28 | 26 | 29 | 25 | 31 | 26 |
| Week 5 | 23 | 25 | 28 | 26 | 28 | 29 | 33 | 27 |
| Week 6 | 23 | 26 | 28 | 27 | 28 | 27 | 31 | 29 |
| Week 7 | 23 | 29 | 29 | 25 | 29 | 27 | 31 | 29 |
| Week 8 | 25 | 26 | 28 | 26 | 26 | 27 | 31 | 29 |
| Week 9 | 24 | 27 | 29 | 26 | 29 | 27 | 32 | 29 |
| Week 10 | 22 | 27 | 26 | 24 | 29 | 29 | 32 | 29 |
| Week 11 | 24 | 29 | 27 | 23 | 27 | 30 | 31 | 30 |
| Week 12 | 23 | 25 | 27 | 21 | 26 | 27 | 31 | 28 |
| Week 13 | 9 | 20 | 15 | 13 | 14 | 20 | 13 | 16 |
| Week 14 | 10 | 17 | 13 | 9 | 10 | 17 | 12 | 13 |
| Week 15 | 9 | 12 | 10 | 8 | 7 | 11 | 10 | 12 |
The HFRDIS is a 10-item scale that measures a woman's perceptions of the degree to which VMS interfere with 9 daily life activities (work, social activities, leisure, sleep, mood, concentration, relations with others, sexuality, and enjoying life); the tenth item measures interference with overall quality of life. This scale was modeled after items on the Brief Pain Inventory and Brief Fatigue Inventory, which assess the extent to which pain or fatigue interfere with daily life. Participants were asked to rate the extent to which VMS had interfered with each item during the previous 2-week time interval using a 0 (do not interfere) to 10 (completely interfere) scale. Overall mean score is the average of individual item scores (sum of items/10).
| Score on a scale | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Week 4 | -2.2 ± 0.34 | -3.3 ± 0.32 | -3.6 ± 0.33 | -3.8 ± 0.33 | -3.7 ± 0.35 | -2.5 ± 0.35 | -3.4 ± 0.32 | -3.5 ± 0.34 |
| Week 8 | -2.7 ± 0.34 | -3.3 ± 0.33 | -3.6 ± 0.34 | -4.1 ± 0.35 | -4.2 ± 0.36 | -3.0 ± 0.36 | -3.3 ± 0.33 | -3.6 ± 0.35 |
| Week 12 | -2.9 ± 0.33 | -3.6 ± 0.31 | -3.8 ± 0.33 | -4.3 ± 0.34 | -4.2 ± 0.35 | -3.3 ± 0.35 | -3.5 ± 0.32 | -3.9 ± 0.33 |
| Week 15 | -2.4 ± 0.39 | -2.6 ± 0.37 | -2.2 ± 0.39 | -2.3 ± 0.40 | -1.9 ± 0.41 | -2.9 ± 0.42 | -2.4 ± 0.38 | -2.5 ± 0.40 |
The LSEQ is a 10-item self-rated questionnaire that assesses a participants aspects of sleep and early morning behavior. The questions are grouped into 4 chronological areas: ease of getting to sleep, perceived quality of sleep, ease of awaking from sleep, and integrity of early morning behavior following wakefulness. The LSEQ is a visual analog scale that requires respondents to place marks on a group of 10 cm lines. Lines extend between extremes like "more difficult than usual" and "easier than usual." Responses are measured using a 100 mm scale and are averaged to a score for each domain. Higher scores indicates better sleep and better early morning behavior.
| Score on a scale | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Week 4: Ease of Getting to Sleep | 40.7 ± 3.18 | 43.1 ± 3.06 | 44.6 ± 3.25 | 36.7 ± 3.25 | 41.7 ± 3.38 | 43.1 ± 3.35 | 40.3 ± 2.98 | 44.7 ± 3.32 |
| Week 4: Quality of Sleep | 38.7 ± 3.75 | 40.4 ± 3.64 | 36.1 ± 3.81 | 32.8 ± 3.84 | 42.0 ± 4.00 | 36.7 ± 3.98 | 38.6 ± 3.53 | 42.4 ± 3.95 |
| Week 4: Ease of Awaking From Sleep | 43.6 ± 3.31 | 47.1 ± 3.18 | 43.9 ± 3.36 | 37.8 ± 3.38 | 41.7 ± 3.53 | 41.8 ± 3.51 | 37.5 ± 3.10 | 43.3 ± 3.48 |
| Week 4: Integrity of Behavior Following Awaking | 41.2 ± 3.40 | 42.0 ± 3.23 | 41.5 ± 3.44 | 32.4 ± 3.44 | 38.0 ± 3.61 | 43.3 ± 3.58 | 41.8 ± 3.16 | 41.3 ± 3.56 |
| Week 8:Ease of Getting to Sleep | 40.3 ± 3.09 | 39.2 ± 2.96 | 41.5 ± 3.10 | 35.6 ± 3.18 | 38.3 ± 3.28 | 41.7 ± 3.24 | 43.6 ± 2.98 | 43.7 ± 3.15 |
| Week 8: Quality of Sleep | 41.1 ± 3.63 | 36.3 ± 3.52 | 39.5 ± 3.62 | 33.6 ± 3.75 | 38.6 ± 3.86 | 36.9 ± 3.83 | 37.7 ± 3.54 | 38.2 ± 3.71 |
| Week 8:Ease of Awaking From Sleep | 40.3 ± 3.35 | 38.8 ± 3.22 | 37.5 ± 3.34 | 36.4 ± 3.46 | 41.2 ± 3.56 | 37.7 ± 3.53 | 44.3 ± 3.27 | 41.2 ± 3.43 |
| Week 8: Integrity of Behavior Following Awake | 40.9 ± 3.49 | 40.6 ± 3.33 | 38.8 ± 3.47 | 35.2 ± 3.56 | 41.4 ± 3.69 | 35.9 ± 3.66 | 41.3 ± 3.36 | 40.5 ± 3.55 |
| Wek 12: Ease of Getting Sleep | 32.0 ± 3.30 | 37.2 ± 3.04 | 38.9 ± 3.41 | 37.7 ± 3.44 | 39.6 ± 3.69 | 39.4 ± 3.78 | 41.6 ± 3.19 | 38.4 ± 3.39 |
| Week 12: Quality of Sleep | 36.3 ± 3.76 | 37.2 ± 3.46 | 38.4 ± 3.89 | 36.0 ± 3.92 | 34.5 ± 4.22 | 37.1 ± 4.35 | 37.6 ± 3.64 | 36.6 ± 3.88 |
| Week 12: Ease of Awaking From Sleep | 37.3 ± 3.68 | 37.1 ± 3.41 | 35.9 ± 3.77 | 37.4 ± 3.82 | 37.8 ± 4.06 | 37.1 ± 4.15 | 41.9 ± 3.57 | 40.9 ± 3.78 |
| Week 12: Integrity of Behavior Following Awaking | 35.5 ± 3.82 | 38.3 ± 3.54 | 36.6 ± 3.90 | 37.3 ± 3.93 | 41.2 ± 4.18 | 35.2 ± 4.27 | 44.2 ± 3.67 | 39.0 ± 3.92 |
| Wek 15:Ease of Getting Sleep | 39.8 ± 3.62 | 39.2 ± 3.29 | 42.8 ± 3.51 | 41.5 ± 3.59 | 49.4 ± 3.91 | 38.8 ± 3.85 | 44.8 ± 3.45 | 44.0 ± 3.64 |
| Week 15: Quality of Sleep | 39.3 ± 4.54 | 34.7 ± 4.19 | 37.1 ± 4.39 | 36.2 ± 4.52 | 45.9 ± 4.95 | 33.0 ± 4.88 | 42.4 ± 4.39 | 41.4 ± 4.60 |
| Week 15: Ease of Awaking From Sleep | 33.9 ± 4.20 | 34.9 ± 3.88 | 37.1 ± 4.08 | 36.1 ± 4.21 | 45.4 ± 4.57 | 35.6 ± 4.51 | 49.4 ± 4.08 | 45.0 ± 4.26 |
| Week 15: Integrity of Behavior Following Awaking | 40.9 ± 4.15 | 35.1 ± 3.81 | 46.7 ± 4.01 | 42.8 ± 4.11 | 50.9 ± 4.48 | 35.9 ± 4.43 | 47.1 ± 3.98 | 43.8 ± 4.19 |
The GCS is a 21-item scale that provides a brief but comprehensive and valid measure of climacteric symptomatology. Each item is rated by the participant according to its severity using a 4-point rating scale from 0 (none) to 3 (severe). The first 20 items of the scale combine into 3 main independent symptom measures by summing up the individual item scores: psychological symptoms (items 1 to 11; score 0 to 33), physical symptoms (items 12 to 18; score 0 to 21), and VMS (items 19 to 20; score 0 to 6). Item 21 is a probe for sexual dysfunction. The total score can range from 0 to 63. Higher scores indicate worse symptoms.
| Score on a scale | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Week 4: Psychological Symptoms | -2.6 ± 0.70 | -3.8 ± 0.66 | -4.5 ± 0.69 | -5.0 ± 0.68 | -4.4 ± 0.71 | -3.7 ± 0.70 | -2.1 ± 0.65 | -4.9 ± 0.71 |
| Week 4: Physical Symptoms | -1.1 ± 0.38 | -1.1 ± 0.37 | -1.6 ± 0.38 | -1.1 ± 0.37 | -1.2 ± 0.39 | -1.4 ± 0.39 | -0.8 ± 0.36 | -1.9 ± 0.39 |
| Week 4: VasomotorSymptoms Score | -1.7 ± 0.27 | -2.1 ± 0.25 | -2.7 ± 0.26 | -3.3 ± 0.26 | -3.2 ± 0.27 | -2.2 ± 0.27 | -2.6 ± 0.25 | -2.9 ± 0.27 |
| Week 4: Sexual Dysfunction Score | -0.4 ± 0.13 | -0.7 ± 0.12 | -0.7 ± 0.13 | -0.9 ± 0.13 | -0.7 ± 0.13 | -0.3 ± 0.13 | -0.4 ± 0.12 | -0.6 ± 0.13 |
| Week 4: Total Score | -6.1 ± 1.17 | -7.8 ± 1.10 | -9.6 ± 1.16 | -10.4 ± 1.15 | -9.5 ± 1.19 | -7.6 ± 1.19 | -5.8 ± 1.10 | -10.3 ± 1.19 |
| Week 8: Psychological Symptoms | -3.3 ± 0.71 | -5.0 ± 0.69 | -4.7 ± 0.71 | -4.9 ± 0.73 | -4.5 ± 0.74 | -3.3 ± 0.73 | -2.8 ± 0.69 | -4.6 ± 0.73 |
| Week 8: Physical Symptoms | -1.1 ± 0.40 | -1.5 ± 0.39 | -1.3 ± 0.40 | -0.8 ± 0.40 | -1.6 ± 0.41 | -1.4 ± 0.41 | -0.9 ± 0.39 | -1.9 ± 0.40 |
| Week 8: VasomotorSymptoms Score | -1.9 ± 0.27 | -2.5 ± 0.26 | -3.0 ± 0.27 | -3.4 ± 0.28 | -3.5 ± 0.28 | -2.2 ± 0.28 | -2.9 ± 0.26 | -3.0 ± 0.28 |
| Week 8: Sexual Dysfunction Score | -0.4 ± 0.14 | -0.5 ± 0.13 | -0.8 ± 0.14 | -0.7 ± 0.14 | -0.6 ± 0.14 | -0.6 ± 0.14 | -0.3 ± 0.13 | -0.8 ± 0.14 |
| Week 8: Total Score | -6.9 ± 1.23 | -9.4 ± 1.18 | -9.9 ± 1.21 | -9.9 ± 1.25 | -10.1 ± 1.27 | -7.6 ± 1.26 | -7.0 ± 1.18 | -10.2 ± 1.24 |
| Week 12: Psychological Symptoms | -3.3 ± 0.73 | -5.0 ± 0.68 | -4.9 ± 0.73 | -4.8 ± 0.75 | -4.3 ± 0.77 | -4.4 ± 0.77 | -3.6 ± 0.70 | -4.9 ± 0.74 |
| Week 12: Physical Symptoms Score | -1.5 ± 0.38 | -2.1 ± 0.36 | -1.0 ± 0.39 | -1.3 ± 0.40 | -1.6 ± 0.41 | -1.7 ± 0.41 | -0.9 ± 0.37 | -1.9 ± 0.39 |
| Week 12: Vasomotor Symptoms Score | -2.1 ± 0.26 | -2.7 ± 0.24 | -3.1 ± 0.26 | -3.6 ± 0.26 | -3.6 ± 0.27 | -2.9 ± 0.27 | -2.8 ± 0.25 | -2.9 ± 0.26 |
| Week 12: Sexual Dysfunction Score | -0.5 ± 0.14 | -0.7 ± 0.13 | -1.1 ± 0.14 | -0.9 ± 0.15 | -0.8 ± 0.15 | -0.5 ± 0.15 | -0.5 ± 0.14 | -0.6 ± 0.14 |
| Week 12: Total Score | -7.6 ± 1.23 | -10.4 ± 1.15 | -10.1 ± 1.23 | -10.7 ± 1.25 | -10.3 ± 1.29 | -9.6 ± 1.29 | -7.8 ± 1.18 | -10.3 ± 1.24 |
| Week 15: Psychological Symptoms Score ; | -2.7 ± 0.82 | -4.6 ± 0.76 | -4.3 ± 0.79 | -2.7 ± 0.82 | -2.3 ± 0.83 | -4.4 ± 0.84 | -2.6 ± 0.79 | -4.1 ± 0.82 |
| Week 15: Physical Symptoms Score | -1.4 ± 0.43 | -1.7 ± 0.40 | -1.8 ± 0.42 | -1.0 ± 0.42 | -1.4 ± 0.43 | -1.4 ± 0.44 | -1.2 ± 0.41 | -2.1 ± 0.43 |
| Week 15: Vasomotor Symptoms Score | -1.4 ± 0.34 | -2.1 ± 0.32 | -1.6 ± 0.33 | -1.7 ± 0.34 | -1.9 ± 0.35 | -1.9 ± 0.35 | -1.8 ± 0.33 | -1.5 ± 0.34 |
| Week 15: Sexual Dysfunction Score | -0.5 ± 0.15 | -0.7 ± 0.14 | -0.6 ± 0.15 | -0.7 ± 0.15 | -0.5 ± 0.15 | -0.7 ± 0.16 | -0.6 ± 0.15 | -0.7 ± 0.15 |
| Week 15: Total Score | -6.3 ± 1.41 | -9.1 ± 1.31 | -8.3 ± 1.37 | -6.3 ± 1.41 | -6.0 ± 1.43 | -8.6 ± 1.44 | -6.3 ± 1.36 | -8.3 ± 1.41 |
The MENQoL is self-administered and consists of a total of 29 items in a Likert-scale format. Each item assesses the impact of 1 of 4 domains of menopausal symptoms, as experienced over the last month: vasomotor (items 1 to 3), psychosocial (items 4 to 10), physical (items 11 to 26), and sexual (items 27 to 29). Items pertaining to a specific symptom are rated as present or not present, and if present, how bothersome on a 0 (not bothersome) to 6 (extremely bothersome) scale. Means are computed for each subscale by dividing the sum of the domain's items by the number of items within that domain. Non-endorsement of an item is scored a "1" and endorsement a "2," plus the number of the particular rating, so that the possible score on any item ranges from 1 to 8. Higher scores indicate that menopause symptoms are more bothersome.
| Score on a scale | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Week 4: Vasomotor Mean Score | -1.8 ± 0.32 | -2.4 ± 0.30 | -3.0 ± 0.32 | -3.4 ± 0.31 | -3.6 ± 0.32 | -1.9 ± 0.32 | -2.4 ± 0.30 | -2.8 ± 0.32 |
| Week 4:Psychological Mean Score | -1.0 ± 0.21 | -1.2 ± 0.20 | -1.3 ± 0.21 | -1.3 ± 0.20 | -1.2 ± 0.21 | -0.8 ± 0.21 | -0.6 ± 0.20 | -1.0 ± 0.21 |
| Week 4: Physical Mean Score | -0.8 ± 0.18 | -1.2 ± 0.17 | -1.4 ± 0.18 | -1.1 ± 0.18 | -1.3 ± 0.19 | -1.1 ± 0.19 | -0.8 ± 0.17 | -1.3 ± 0.19 |
| Week 4: Sexual Mean Score | -0.7 ± 0.27 | -1.5 ± 0.25 | -1.8 ± 0.27 | -1.4 ± 0.26 | -1.2 ± 0.27 | -0.8 ± 0.28 | -0.7 ± 0.25 | -1.2 ± 0.27 |
| Week 4: Overall Mean Score | -0.9 ± 0.18 | -1.3 ± 0.17 | -1.6 ± 0.18 | -1.4 ± 0.17 | -1.5 ± 0.18 | -1.1 ± 0.18 | -0.9 ± 0.17 | -1.3 ± 0.18 |
| Week 8: Vasomotor Mean Score | -2.1 ± 0.31 | -2.6 ± 0.30 | -3.4 ± 0.31 | -3.8 ± 0.31 | -4.1 ± 0.32 | -2.5 ± 0.32 | -3.1 ± 0.30 | -3.4 ± 0.32 |
| Week 8: Psychological Mean Score | -1.2 ± 0.20 | -1.2 ± 0.19 | -1.3 ± 0.20 | -1.4 ± 0.20 | -1.3 ± 0.21 | -1.0 ± 0.20 | -1.0 ± 0.19 | -1.1 ± 0.20 |
| Week 8: Physical Mean Score | -1.0 ± 0.19 | -1.2 ± 0.18 | -1.5 ± 0.19 | -1.4 ± 0.19 | -1.5 ± 0.19 | -1.3 ± 0.19 | -1.0 ± 0.18 | -1.3 ± 0.19 |
| Week 8: Sexual Mean Score | -0.9 ± 0.26 | -1.0 ± 0.25 | -1.7 ± 0.26 | -1.2 ± 0.27 | -1.2 ± 0.27 | -1.3 ± 0.27 | -0.8 ± 0.25 | -1.2 ± 0.27 |
| Week 8: Overall Mean Score | -1.2 ± 0.18 | -1.3 ± 0.17 | -1.7 ± 0.18 | -1.6 ± 0.18 | -1.7 ± 0.18 | -1.4 ± 0.18 | -1.2 ± 0.17 | -1.5 ± 0.18 |
| Week 12: Vasomotor Mean Score | -2.3 ± 0.31 | -3.2 ± 0.29 | -3.5 ± 0.31 | -3.8 ± 0.31 | -4.4 ± 0.32 | -2.9 ± 0.32 | -3.3 ± 0.30 | -3.6 ± 0.31 |
| Week 12: Psychological Mean Score | -1.3 ± 0.20 | -1.3 ± 0.19 | -1.7 ± 0.20 | -1.5 ± 0.21 | -1.4 ± 0.22 | -1.0 ± 0.22 | -1.1 ± 0.20 | -1.2 ± 0.21 |
| Week 12: Physical Mean Score | -1.3 ± 0.19 | -1.4 ± 0.18 | -1.6 ± 0.19 | -1.4 ± 0.19 | -1.5 ± 0.20 | -1.4 ± 0.20 | -1.0 ± 0.18 | -1.4 ± 0.19 |
| Week 12: Sexual Score | -0.8 ± 0.29 | -0.9 ± 0.27 | -1.8 ± 0.29 | -1.4 ± 0.29 | -0.9 ± 0.30 | -1.4 ± 0.31 | -0.8 ± 0.28 | -1.3 ± 0.29 |
| Week 12: Overall Mean Score | -1.3 ± 0.18 | -1.5 ± 0.17 | -1.8 ± 0.18 | -1.7 ± 0.18 | -1.7 ± 0.19 | -1.5 ± 0.19 | -1.3 ± 0.17 | -1.6 ± 0.18 |
| Week 15: Vasomotor Mean Score | -1.8 ± 0.36 | -2.1 ± 0.34 | -1.7 ± 0.36 | -1.4 ± 0.37 | -1.7 ± 0.37 | -2.1 ± 0.38 | -2.2 ± 0.35 | -1.3 ± 0.37 |
| Week 15: Psychological Mean Score | -1.0 ± 0.23 | -1.0 ± 0.22 | -1.3 ± 0.23 | -1.1 ± 0.23 | -0.9 ± 0.24 | -1.2 ± 0.24 | -0.9 ± 0.22 | -1.0 ± 0.23 |
| Week 15: Physical Mean Score | -1.2 ± 0.20 | -1.3 ± 0.18 | -1.5 ± 0.19 | -0.9 ± 0.20 | -1.2 ± 0.20 | -1.4 ± 0.20 | -1.0 ± 0.19 | -1.2 ± 0.20 |
| Week 15: Sexual Mean Score | -0.6 ± 0.30 | -0.9 ± 0.28 | -1.5 ± 0.30 | -1.4 ± 0.30 | -0.6 ± 0.31 | -1.3 ± 0.32 | -0.6 ± 0.29 | -1.2 ± 0.30 |
| Week 15: Overall Mean Score | -1.1 ± 0.19 | -1.3 ± 0.18 | -1.5 ± 0.19 | -1.1 ± 0.19 | -1.2 ± 0.20 | -1.4 ± 0.21 | -1.0 ± 0.19 | -1.2 ± 0.20 |
Change was calculated as the post-baseline measurement minus the baseline measurement. Baseline was the last measurement taken prior to initial study drug administration.
| International unit per liter (IU/L) | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Change Over Time From Baseline in Plasma Concentrations of Luteinizing Hormone (LH) at Week 12 | -1.14 ± 8.00 | -1.28 ± 8.53 | -3.28 ± 8.93 | -7.30 ± 15.49 | -10.86 ± 12.64 | -3.69 ± 11.21 | -3.97 ± 9.55 | -8.62 ± 11.95 |
Change was calculated as the post-baseline measurement minus the baseline measurement. Baseline was the last measurement taken prior to initial study drug administration.
| IU/L | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Change Over Time From Baseline in Plasma Concentrations of Follicle-Stimulating Hormone (FSH) at Week 12 | -0.91 ± 9.79 | -1.52 ± 12.88 | -1.00 ± 13.51 | -6.49 ± 25.58 | -9.43 ± 17.40 | -0.98 ± 26.90 | -0.07 ± 8.97 | -9.94 ± 16.96 |
Change was calculated as the post-baseline measurement minus the baseline measurement. Baseline was the last measurement taken prior to initial study drug administration. The analysis value for Estradiol was imputed as 73.4/2 = 36.7 when result was \< 73.4.
| picomole per milliliter (pmol/L) | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Change Over Time From Baseline in Plasma Concentrations of Estradiol (E2) at Week 12 | 1.49 ± 7.41 | -1.29 ± 53.58 | 20.47 ± 93.37 | 10.15 ± 96.52 | -4.85 ± 56.56 | -15.99 ± 213.04 | -32.08 ± 198.54 | 1.32 ± 5.68 |
Change was calculated as the post-baseline measurement minus the baseline measurement. Baseline was the last measurement taken prior to initial study drug administration.
| Nanomole per liter (nmol/L) | Placebo | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Change Over Time From Baseline in Plasma Concentrations of Sex Hormone-Binding Globulin (SHBG) at Week 12 | 1.877 ± 12.270 | 0.720 ± 14.220 | 4.867 ± 10.492 | 1.621 ± 16.329 | 6.643 ± 11.107 | 2.350 ± 17.852 | 0.143 ± 8.741 | 0.583 ± 14.283 |
Collected over From date of informed consent until end of the study (up to 15 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo BID | 0/43 (0%) | 0/43 (0%) | 5/43 (11.6%) |
| Fezolinetant 15 mg BID | 0/45 (0%) | 0/45 (0%) | 9/45 (20%) |
| Fezolinetant 30 mg BID | 0/43 (0%) | 0/43 (0%) | 7/43 (16.3%) |
| Fezolinetant 60 mg BID | 0/45 (0%) | 0/45 (0%) | 11/45 (24.4%) |
| Fezolinetant 90 mg BID | 0/44 (0%) | 0/44 (0%) | 11/44 (25%) |
| Fezolinetant 30 mg QD | 0/43 (0%) | 0/43 (0%) | 12/43 (27.9%) |
| Fezolinetant 60 mg QD | 0/45 (0%) | 1/45 (2.2%) | 14/45 (31.1%) |
| Fezolinetant 120 mg QD | 0/44 (0%) | 0/44 (0%) | 11/44 (25%) |
| Event | Placebo BID | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/43 | 0/45 | 0/43 | 0/45 | 0/44 | 0/43 | 1/45 | 0/44 |
| Event | Placebo BID | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD |
|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 2/43 | 3/45 | 2/43 | 2/45 | 1/44 | 6/43 | 3/45 | 4/44 |
| NauseaGastrointestinal disorders | 1/43 | 1/45 | 3/43 | 3/45 | 1/44 | 2/43 | 3/45 | 2/44 |
| Upper respiratory tract infectionInfections and infestations | 1/43 | 2/45 | 1/43 | 1/45 | 1/44 | 3/43 | 1/45 | 1/44 |
| Urinary tract infectionInfections and infestations | 1/43 | 2/45 | 1/43 | 2/45 | 2/44 | 2/43 | 2/45 | 3/44 |
| Viral upper respiratory tract infectionInfections and infestations | 0/43 | 2/45 | 1/43 | 1/45 | 3/44 | 0/43 | 0/45 | 0/44 |
| DiarrhoeaGastrointestinal disorders | 1/43 | 0/45 | 1/43 | 2/45 | 2/44 | 1/43 | 3/45 | 0/44 |
| FatigueGeneral disorders | 0/43 | 1/45 | 1/43 | 1/45 | 2/44 | 0/43 | 3/45 | 1/44 |
| SinusitisInfections and infestations | 0/43 | 0/45 | 0/43 | 3/45 | 0/44 | 1/43 | 2/45 | 0/44 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/43 | 1/45 | 0/43 | 1/45 | 0/44 | 0/43 | 3/45 | 0/44 |
The safety analysis set (SAF) consisted of all randomized participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Placebo BID | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 54.8 ± 5.5 | 53.7 ± 5.0 | 53.9 ± 3.8 | 54.6 ± 5.0 | 54.9 ± 4.0 | 52.7 ± 3.8 | 55.0 ± 4.9 | 56.8 ± 4.4 | 54.6 ± 4.7 |
| Sex: Female, Male(Participants) | Placebo BID | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 43 | 45 | 43 | 45 | 44 | 43 | 45 | 44 | 352 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Placebo BID | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 15 | 16 | 9 | 13 | 10 | 17 | 12 | 9 | 101 |
| Not Hispanic or Latino | 28 | 29 | 34 | 32 | 34 | 26 | 33 | 35 | 251 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo BID | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 |
| Asian | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 10 | 8 | 12 | 15 | 8 | 11 | 10 | 13 | 87 |
| White | 30 | 37 | 31 | 28 | 36 | 31 | 34 | 30 | 257 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 3 |
| Frequency of Moderate and Severe Vasomotor Symptoms per 24h(VMS per day) | Placebo BID | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 9.71 ± 3.53 | 11.12 ± 7.13 | 9.85 ± 4.62 | 9.48 ± 3.97 | 9.32 ± 3.59 | 11.18 ± 6.44 | 9.42 ± 2.70 | 9.65 ± 3.73 | 9.97 ± 4.71 |
| Severity of Moderate and Severe Vasomotor Symptoms per 24h(Score on a scale) | Placebo BID | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 2.46 ± 0.31 | 2.45 ± 0.27 | 2.43 ± 0.31 | 2.45 ± 0.31 | 2.38 ± 0.30 | 2.43 ± 0.30 | 2.40 ± 0.26 | 2.49 ± 0.32 | 2.44 ± 0.30 |
| Frequency of Mild, Moderate, and Severe Vasomotor Symptoms per 24h(VMS per day) | Placebo BID | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 9.96 ± 3.49 | 11.63 ± 7.10 | 10.33 ± 4.88 | 10.14 ± 4.22 | 9.85 ± 4.31 | 11.72 ± 6.66 | 10.15 ± 2.86 | 10.15 ± 3.78 | 10.5 ± 4.88 |
| Severity of Mild, Moderate, and Severe Vasomotor Symptoms per 24h(Score on a scale) | Placebo BID | Fezolinetant 15 mg BID | Fezolinetant 30 mg BID | Fezolinetant 60 mg BID | Fezolinetant 90 mg BID | Fezolinetant 30 mg QD | Fezolinetant 60 mg QD | Fezolinetant 120 mg QD | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 2.43 ± 0.32 | 2.38 ± 0.29 | 2.37 ± 0.33 | 2.38 ± 0.36 | 2.33 ± 0.33 | 2.38 ± 0.34 | 2.31 ± 0.31 | 2.43 ± 0.37 | 2.38 ± 0.33 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Ran from Jul 2017 to primary completion in Sep 2018, 14 months.
Results were first posted in Sep 2021, 3 years after primary completion. A results delay was requested in Sep 2019.
Of 24 phase 2 interventional studies under Hot Flashes, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 54. This study's 14 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fezolinetant
Astellas Pharma Global Development, Inc. →